These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 37864849)

  • 1. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study.
    Fontán-Vela M; Hernando V; Olmedo C; Coma E; Martínez M; Moreno-Perez D; Lorusso N; Vázquez Torres M; Barbas Del Buey JF; Roig-Sena J; Pastor E; Galmés Truyols A; Artigues Serra F; Sancho Martínez RM; Latasa Zamalloa P; Pérez Martínez O; Vázquez Estepa A; García Rojas AJ; Barreno Estévez AI; Sánchez-Migallón Naranjo A; Pérez Martín JJ; Peces Jiménez P; Morales Romero R; Castilla J; García Cenoz M; Huerta Huerta M; Boone ALD; Macías Ortiz MJ; Álvarez Río V; Rodríguez Recio MJ; Merino Díaz M; Berradre Sáenz B; Villegas-Moreno MT; Limia A; Diaz A; Monge S;
    Clin Infect Dis; 2024 Feb; 78(2):476-483. PubMed ID: 37864849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
    Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
    Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
    Merad Y; Gaymard A; Cotte L; Perpoint T; Alfaiate D; Godinot M; Becker A; Cannesson O; Batalla AS; Oria-Yassir F; Landré S; Morfin F; Bouscambert M; Valour F; Ader F; Conrad A
    Euro Surveill; 2022 Dec; 27(50):. PubMed ID: 36695469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial.
    Navarro C; Lau C; Buchan SA; Burchell AN; Nasreen S; Friedman L; Okpokoro E; Austin PC; Tan DHS; Gubbay JB; Kwong JC; Mishra S;
    BMJ; 2024 Sep; 386():e078243. PubMed ID: 39260880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
    Mazzotta V; Lepri AC; Matusali G; Cimini E; Piselli P; Aguglia C; Lanini S; Colavita F; Notari S; Oliva A; Meschi S; Casetti R; Mondillo V; Vergori A; Bettini A; Grassi G; Pinnetti C; Lapa D; Tartaglia E; Gallì P; Mondi A; Montagnari G; Gagliardini R; Nicastri E; Lichtner M; Sarmati L; Tamburrini E; Mastroianni C; Stingone C; Siddu A; Barca A; Fontana C; Agrati C; Girardi E; Vaia F; Maggi F; Antinori A;
    EClinicalMedicine; 2024 Feb; 68():102420. PubMed ID: 38292040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
    Muller MP; Navarro C; Wilson SE; Shulha HP; Naus M; Lim G; Padhi S; McGeer A; Finkelstein M; Liddy A; Bettinger JA;
    Vaccine; 2024 Jan; 42(3):535-540. PubMed ID: 38199921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of a single dose of mpox vaccine in males.
    Wolff Sagy Y; Zucker R; Hammerman A; Markovits H; Arieh NG; Abu Ahmad W; Battat E; Ramot N; Carmeli G; Mark-Amir A; Wagner-Kolasko G; Duskin-Bitan H; Yaron S; Peretz A; Arbel R; Lavie G; Netzer D
    Nat Med; 2023 Mar; 29(3):748-752. PubMed ID: 36720271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the acute antibody response of monkeypox and MVA-BN vaccine following an Australian outbreak.
    Asquith W; Hueston L; Dwyer D; Kok J; Ko D; Fennel M; Rockett R; Rai NJ; Li Y; Sriramoju S; Sutor A; O'Sullivan M
    J Med Virol; 2024 Jan; 96(1):e29407. PubMed ID: 38240403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of mpox infection in individuals who received a first dose of modified vaccinia Ankara immunisation.
    Agunbiade S; Burton F; Muirhead J; Whitlock GG; Girometti N
    Sex Transm Infect; 2023 May; 99(3):198-199. PubMed ID: 36596674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings.
    Mason LMK; Betancur E; Riera-Montes M; Lienert F; Scheele S
    Vaccine; 2024 Dec; 42(26):126409. PubMed ID: 39413490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines against mpox: MVA-BN and LC16m8.
    Grabenstein JD; Hacker A
    Expert Rev Vaccines; 2024; 23(1):796-811. PubMed ID: 39188013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.
    Pischel L; Martini BA; Yu N; Cacesse D; Tracy M; Kharbanda K; Ahmed N; Patel KM; Grimshaw AA; Malik AA; Goshua G; Omer SB
    Vaccine; 2024 Nov; 42(25):126053. PubMed ID: 38906763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines.
    Cornelisse VJ; Kearley JJM; Vargas Castillo J; Macharg L; McLaughlin VA; Jack SJ; Swift C
    Sex Health; 2023 Dec; 20(6):585-587. PubMed ID: 37852607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Zaeck LM; Lamers MM; Verstrepen BE; Bestebroer TM; van Royen ME; Götz H; Shamier MC; van Leeuwen LPM; Schmitz KS; Alblas K; van Efferen S; Bogers S; Scherbeijn S; Rimmelzwaan GF; van Gorp ECM; Koopmans MPG; Haagmans BL; GeurtsvanKessel CH; de Vries RD
    Nat Med; 2023 Jan; 29(1):270-278. PubMed ID: 36257333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023.
    Dalton AF; Diallo AO; Chard AN; Moulia DL; Deputy NP; Fothergill A; Kracalik I; Wegner CW; Markus TM; Pathela P; Still WL; Hawkins S; Mangla AT; Ravi N; Licherdell E; Britton A; Lynfield R; Sutton M; Hansen AP; Betancourt GS; Rowlands JV; Chai SJ; Fisher R; Danza P; Farley M; Zipprich J; Prahl G; Wendel KA; Niccolai L; Castilho JL; Payne DC; Cohn AC; Feldstein LR; ;
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):553-558. PubMed ID: 37200229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic and Subclinical Mpox: An Association With Modified Vaccinia Ankara Vaccine.
    Golden MR; Soge OO; Mills M; Berzkalns A; Cannon C; Ramchandani M; Dombrowski JC; Karmarkar EN; Chow EJ; Gov JP; Swenson P; Greninger AL
    Sex Transm Dis; 2024 May; 51(5):342-347. PubMed ID: 38301634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting vaccine effectiveness for mpox.
    Berry MT; Khan SR; Schlub TE; Notaras A; Kunasekaran M; Grulich AE; MacIntyre CR; Davenport MP; Khoury DS
    Nat Commun; 2024 May; 15(1):3856. PubMed ID: 38719852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Status of Vaccine Development for Monkeypox Virus.
    Rastogi A; Kumar M
    Adv Exp Med Biol; 2024; 1451():289-300. PubMed ID: 38801585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.
    Hubert M; Guivel-Benhassine F; Bruel T; Porrot F; Planas D; Vanhomwegen J; Wiedemann A; Burrel S; Marot S; Palich R; Monsel G; Diombera H; Gallien S; Lopez-Zaragoza JL; Vindrios W; Taieb F; Fernandes-Pellerin S; Delhaye M; Laude H; Arowas L; Ungeheuer MN; Hocqueloux L; Pourcher V; Prazuck T; Marcelin AG; Lelièvre JD; Batéjat C; Lévy Y; Manuguerra JC; Schwartz O
    Cell Host Microbe; 2023 Jun; 31(6):937-948.e4. PubMed ID: 37196656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.